Correspondence 0001104659-24-062826 from Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc.
Date: May 17, 2024 · CIK: 0001815903 · Accession: 0001104659-24-062826
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279116
Letter
Petros Pharmaceuticals, Inc.
1185 Avenue of the Americas, 3rd Floor
New York, New York 10036
May 17, 2024
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
Washington, D.C. 20549
Attention: Doris Stacey Gama
Re: Petros Pharmaceuticals, Inc.
Registration Statement on Form S-3
Originally filed on May 3, 2024
File No. 333-279116 (the “Registration Statement”)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, Petros Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests acceleration of the effective date of the Registration Statement, so that it may become effective at 4:30 p.m., Eastern Time, on May 20, 2024, or as soon thereafter as practicable.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Alla Digilova, Esq. at (212) 659-4993.
Very truly yours,
PETROS Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Petros Pharmaceuticals, Inc.
1185 Avenue of the Americas, 3rd Floor
New York, New York 10036
May 17, 2024
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
Washington, D.C. 20549
Attention: Doris Stacey Gama
Re:
Petros Pharmaceuticals, Inc.
Registration Statement on Form S-3
Originally filed on May 3, 2024
File No. 333-279116 (the “Registration Statement”)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 of the
Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act
of 1933, as amended, Petros Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests acceleration
of the effective date of the Registration Statement, so that it may become effective at 4:30 p.m., Eastern Time, on May 20, 2024, or as
soon thereafter as practicable.
Should any member of the staff
of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention:
Alla Digilova, Esq. at (212) 659-4993.
Very truly yours,
PETROS Pharmaceuticals, Inc.
By:
/s/ Fady Boctor
Fady Boctor
Chief Executive Officer
cc: Alla Digilova, Esq., Haynes and Boone, LLP